AstraZeneca's ADC disappoints - on severe adverse eventsJuly 03, 2023 - "Should toxicity prove to be worse than feared, strong efficacy becomes even more important. The safety fear here is interstitial lung disease, a known problem for Daiichi Sankyo’s ADCs. The Her2-directed Enhertu carries a boxed warning about ILD, and this side-effect has also been seen in earlier datopotamab studies, albeit without causing deaths."
"Today’s cautiously worded press release, which omitted any actual numbers but included the admission of patient deaths, knocked confidence in the project’s potential. "
https://www.evaluate.com/vantage/articles/news/trial-results/astrazeneca-and-daiichis-big-reveal-disappoints